Blood-based biomarkers accurately predict neuroendocrine tumor response to radiopharmaceutical therapy
A simple blood draw can provide physicians with valuable information that can determine if peptide receptor radionuclide therapy (PRRT) is likely to be effective in a patient with neuroendocrine cancer.
Apr 6, 2023
0
0